Euhearing Therapeutics

Euhearing Therapeutics is a clinical-stage biotechnology company specialized in developing innovative gene therapies for hereditary hearing loss. Based in Shanghai, the company utilizes a proprietary dual-vector adeno-associated virus (AAV) platform to deliver large therapeutic genes that exceed the standard packaging capacity of single AAV vectors. Its lead candidate, EHT102, is an investigational gene therapy designed to treat congenital deafness caused by mutations in the otoferlin (OTOF) gene, also known as DFNB9. Euhearing maintains strong academic and clinical ties with the Eye & ENT Hospital of Fudan University and is advancing its pipeline through clinical trials in both China and the United States.